☆ 4.7 Article

Phase II study of selumetinib (sel) versus temozolomide (TMZ) in gnaq/Gna11 (Gq/11) mutant (mut) uveal melanoma (UM).

JOURNAL OF CLINICAL ONCOLOGY (2017)

Journal

JOURNAL OF CLINICAL ONCOLOGY

Volume 31, Issue 18_suppl, Pages CRA9003-CRA9003

Publisher

American Society of Clinical Oncology (ASCO)

DOI: 10.1200/jco.2013.31.18_suppl.cra9003

Keywords

-

Categories

Oncology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

No Data Available

No Data Available

No Data Available

© Peeref 2019-2024. All rights reserved.